Log In
BCIQ
Print this Print this
 

BCR/ABL1 Quant Test

  Manage Alerts
Collapse Summary General Information
Company Asuragen Inc.
DescriptionTest for monitoring BCR-ABL1 to ABL1 ratio by reverse transcription quantitative polymerase chain reaction (RT-qPCR) on whole blood or bone marrow
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsMonitor treatment response in Philadelphia chromosome positive chronic myelogenous leukemia (CML) patients
Regulatory Designation
PartnerThermo Fisher Scientific Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today